This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from Candida spp. Human antibody encoding genes targeting clinically relevant Candida epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines.

A method for determining whether a test sample contains a phytopathogenic fungus, which includes (a) putting the test sample on a front surface of a substrate having a through hole; the substrate having a cellulose film on the back surface thereof; the through hole has a cross-sectional area of not less than 7.065 square micrometers and not more than 19.625 square micrometers; and the cellulose film has a thickness of not less than 0.5 micrometers and not more than 3.7 micrometers; (b) leaving the test sample at rest after the step (a); (c) irradiating the cellulose film with ultraviolet light after the step (b); (d) bringing a back surface of the cellulose film into contact with a fungus color reaction reagent after the step (c); and (e) determining that the test sample contains the phytopathogenic fungus, if a color is given to the fungus color reaction reagent.

Disclosed herein are methods for selecting a patient suffering from fungal-associated intestinal inflammation for treatment with an IL-1 pathway inhibitor, including inflammasome-blocking drugs based on the presence of candidalysin-secreting C. albicans strains in gut tissue.

Disclosed herein are methods of detecting microbial infection in mammalian subjects comprising treatment of a sample and detection of galactofuranose (galF)-containing antigenic components utilizing monoclonal antibodies. The methods disclosed provide for pretreatment of biological samples, such as urine samples, to maximize detection of galF antigens and improvement of sensitivity of galF antigen detection assays. The methods include minimizing intelectin-1 binding to galF antigens and improvement of monoclonal antibody binding. The detection methods are useful for identifying the presence of microbial antigens related to bacterial, fungal, and parasitic pathogens, including Streptococcus pneumoniae, Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, Histoplasma species, and Leishmania species.

A single unit, handheld field portable apparatus and method for analyzing Ochratoxin A (OTA) in rice quality monitoring, based on fluorescence signal output. Aliquots may be analyzed by adding at least one or more reagents to the sample aliquot that reacts selectively with an analyte contained therein. The reaction product, which is selective for the analyte of interest and proportional to its concentration, is measured with an appropriate detector. This enables simple and accurate testing of samples using time honored wet-chemical analysis method in microliter volume regimes while producing remarkably small volumes of waste. The device includes a multipurpose controller board for processing and analysis purpose, a camera which is integrated with the controller, a resistive touch liquid crystal display to view the results, a light emitting diode to emit the UV light, and a power bank. The device may operate using a touch display.

It is provided novel anti-galactofuranose antibodies and their use for diagnosis of and/or treating aspergillosis, and for the design of chimeric antigen receptor T-cells, wherein single chain variable fragment of the antibodies, such as a heavy chain variable region or a light chain variable region, is fused via a spacer and a transmembrane domain to a signaling endodomain to generate an expression cassette that will be integrated into a T cell.

A biorecognition element for rapid detection of fuel biocontamination. The biorecognition element is a biorecognition element selected from SEQ. ID No. 2 through SEQ. ID No. 24, SEQ. ID No. 22 through SEQ. ID No. 44, SEQ. ID No. 46 through SEQ. ID No. 57, SEQ. ID No. 59 through SEQ. ID No. 196 or SEQ. ID No. 198 through SEQ. ID No. 332.

Materials and methods for detecting and treating Coccidioidomycosis (Valley Fever) are provided herein. For example, materials and methods for enriching and detecting biomarker antigens (e.g., polypeptides and/or glycans) from Coccidioides immitis and Coccidioides posadasii, the fungi that cause Valley Fever, are described herein, as are methods for treating an individual for Valley Fever based on the results of the described detection methods.

The present invention relates to a method for the diagnosis, prognosis, risk assessment, risk stratification, monitoring, therapy guidance and/or therapy control of a fungal infection, in particular invasive fungal infections (IFI) and/or the ruling in or ruling out of an fungal infection and/or the differential diagnosis of a fungal colonization vs. an invasive fungal infection in a subject, wherein in particular the subject has an increased risk of getting or having a fungal infection and/or the subject is in a critical disease state, particularly has an existing infection and/or a state of sepsis, particularly a septic shock. The method of the invention comprises determining the level of at least one marker selected from the group of ICAM1, AHSG, CPN1, FABP1, HRG, PIGR, RAP1A, THBS1, VCL, ET-1. Furthermore, the invention relates to a diagnostic assay and a kit for carrying out the method.

The invention relates to a method for labeling specifically living microorganisms in a sample comprising microorganisms, the method comprising the steps of: a) incubating said microorganisms of said sample with at least one modified monosaccharide compound comprising a first reactive chemical group capable to chemically react with a second reactive group, so that a residue bearing said first reactive group is incorporated into such microorganisms, and b) contacting said residue incorporated in the microorganisms, with a labeling molecule comprising a said second reactive group, for generating the chemical reaction of said first reactive group of said residue incorporated within said living microorganisms with said second reactive group of said labeling molecule, resulting in a covalent link, characterized in that the said modified monosaccharide compound has the following formula (I′), or a salt thereof: —X can be O, NH or S, preferably O and NH, and —R1 and R2 can be independently H, OH, NH.sub.2, OH and NH.sub.2 being substituted or not by protecting groups thereof, preferably substituted by alkyl, hydroxyalkyl, acyl, formyl or imidoyl groups, and —R3 is H or an alkyl chain in C.sub.1 to C.sub.4, each carbon being substituted or not substituted by OH or NH.sub.2 substituted or not by protecting groups thereof, preferably by alkyl, hydroxyalkyl, acyl, formyl or imidoyl groups, and —at least one of X, R1, R2 and R3 groups, preferably R3, being substituted by a said first reactive group Ra. ##STR00001##